Physician profile
Sameer A Mahesh
NPI 1447407697
$1,351.55
in general payments reported to CMS, 2019-2025
8 companies · $18.79 in 2025
The $18.79 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.28 · 2020: $12.99 · 2021: $810 · 2022: $280 · 2023: $183 · 2025: $18.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $167 · Food and Beverage: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $166.66 |
| Food and Beverage | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,225.66 | 2019-2023 | |
| Reflexion Medical, INC. | $30.16 | 2022 | |
| Merck Sharp & Dohme LLC | $28.27 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.79 | 2025 | Opdivo |
| Daiichi Sankyo INC. | $16.16 | 2023 | Injectafer |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Mahesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.